As stated in Valeant's Standards of Business Conduct, Valeant is committed to complying with all applicable U.S. laws and regulations and adhering to the highest ethical standards in its marketing, promotional, educational and research activities. A Comprehensive Compliance Program ("CCP") has been established by Valeant in accordance with California Health and Safety Codes §§ 119400 – 119402. Valeant, to the best of its knowledge and based on its good faith understanding of the statutory requirements, affirms that it is in compliance with this CCP and the referenced statutory requirements.
As the April 2003 Compliance Program Guidance for Pharmaceutical Manufacturers published by the U.S. Department of Health and Human Services, Office of Inspector General (“OIG Guidance”) acknowledges that even with an effective CCP in place, the possibility that an individual employee engaging in conduct that can be considered improper or unethical cannot be completely eliminated. Valeant’s CCP was developed with the goal of preventing and detecting such improper conduct.
This Declaration is effective as of April 1, 2016 for the January 1, 2015 through December 31, 2015 declaration period. The CCP is a fluid and ever-changing program that is designed to meet the evolving regulatory and legislative climate. This program will be assessed on an annual basis.
A copy of this Declaration can be obtained by calling the toll-free number 1-866-246-8245 Ext. 1709 or from www.valeant.com.